Structure-based design of TACE selective inhibitors: Manipulations in the S1′-S3′ pocket

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 18, 2007, Pages 6170-6181

  Huang, Adrian ^a   Joseph McCarthy, Diane ^a   Lovering, Frank ^a   Sun, Linhong ^a   Wang, Weiheng ^a   Xu, Weixin ^a   Zhu, Yi ^a   Cui, Junqing ^a   Zhang, Yuhua ^a   Levin, Jeremy I ^b  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

Sulfone hydroxamates; MMP selectivity; TACE inhibitors

Indexed keywords

4 (4 BUT 2 YNYLAMINOBENZENESULFONYLMETHYL) 1 ISOBUTYRYLPIPERIDINE 4 CARBOXYLIC ACID HYDROXYAMIDE; BETA SULFONYL HYDROXAMATE; COLLAGENASE 3; GELATINASE A; HYDROXAMIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADAM PROTEINS; ANIMALS; ENZYME INHIBITORS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447617899     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.06.031     Document Type: Article

References (27)

1. Feldmann M., Brennan F.M., Williams R.O., Cope A.P., Gibbons D.L., Katsikis P.D., and Maini R.N. Prog. Growth Factor Res. 4 (1992) 247
2. Van Assche G., and Rutgeerts P. Expert Opin. Invest. Drugs 9 (2000) 103
3. Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., and Breathnach S.M. Clin. Exp. Immunol. 94 (1993) 354
4. Feldmann M., and Ravinder N.M. Annu. Rev. Immunol. 19 (2001) 163
5. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., and Cerretti D.P. Nature 385 (1997) 729
6. Moss M.L., Jin S.-L.C., Milla M.E., Burkhart W., Carter H.L., Chen W.-J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R., Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F., Seaton T., Su J.-L., Warner J., Willard D., and Becherer J.D. Nature 385 (1997) 733
7. Stocker W., Grams F., Baumann U., Reinemer P., Gomis-Ruth F.-X., Mckay D.B., and Bode W. Protein Sci. 4 (1995) 823
8. Hooper N.M. FEBS Lett. 354 (1994) 1
9. Maskos K., Fernandez-Catalan C., Huber R., Bourenkov G., Bartunik H., Ellestad G., Reddy P., Wolfson M., Rauch C., Castner B., Davis R., Clarke H., Petersen M., Fitzner J., Cerretti D., March C., Paxton R., Black R., and Bode W. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3408
10. Grootveld M., and McDermott M.F. Curr. Opin. Invest. Drugs 4 (2003) 598
11. Duan J.J.-W., Lu Z., Xue C.-B., He X., Seng J.L., Roderick J.J., Wasserman Z.R., Liu R.-Q., Covington M.B., Magolda R.L., Newton R.C., Trzaskos J.M., and Decicco C.P. Bioorg. Med. Chem. Lett. 13 (2003) 2035
12. Trifilieff A., Walker C., Keller T., Kottirsch G., and Neumann U. Br. J. Pharmacol. 135 (2002) 1655
13. Beck G., Bottomley G., Bradshaw D., Brewster M., Broadhurst M., Devos R., Hill C., Johnson W., Kim H.-J., Kirtland S., Kneer J., Lad N., Mackenzie R., Martin R., Nixon J., Price G., Rodwell A., Rose F., Tang J.-P., Walter D.S., Wilson K., and Worth E. J. Pharmacol. Exp. Ther. 302 (2002) 390
14. Peterson J.T. Heart Fail. Rev. 9 (2004) 63
15. Renkiewicz R., Qiu L., Lesch C., Sun X., Devalaraja R., Cody T., Kaldjian E., Welgus H., and Baragi V. Arthritis Rheum. 48 (2003) 1742
16. Park K., Aplasca A., Du M., Sun L., Zhu Y., Zhang Y., and Levin J.I. Bioorg. Med. Chem. Lett. 16 (2006) 3927
17. Levin, J. I.; Venkatesan, A. M.; Chen, J. M.; Zask, A.; Sandanayaka, V. P.; Du, M. T.; Baker, J. L. U.S. 6358980, 2002.
18. Huang, A.; Condon, J.; Joseph-McCarthy, D.; Lombart, H.; Lovering, F.; Park, K.; Rao, V.; Sun, L.; Wang, Q.; Wang, W.; Xu, W.; Zeng, C.; Zhang, Y.; Zhu, Z.; Levin, J. I. Poster, AAPS Conference: Critical Issues in Discovering Quality Clinical Candidates, Philadelphia, PA, April 24-26, 2006.
19. Zask A., Kaplan J., Du X., MacEwan G., Sandanayaka V., Eudy N., Levin J., Jin G., Xu J., Cummons T., Barone D., Ayral-Kaloustian S., and Skotnicki J. Bioorg. Med. Chem. Lett. 15 (2005) 1641
20. Levin J.I., Chen J.M., Laakso L.M., Du M., Du X., Venkatesan A.M., Sandanayaka V., Zask A., Xu J., Xu W., Zhang Y., and Skotnicki J.S. Bioorg. Med. Chem. Lett. 15 (2005) 4345
21. Tsukida T., Moriyama H., Inoue Y., Kondo H., Yoshino K., and Nishimura S. Bioorg. Med. Chem. Lett. 14 (2004) 1569
22. Moriyama H., Tsukida T., Inoue Y., Yokota K., Yoshino K., Kondo H., Miura N., and Nishimura S.-I. J. Med. Chem. 47 (2004) 1930
23. ** level of theory, including a Poisson-Boltzmann self-consistent reaction field model to account for the effects of aqueous solvation.
24. The RCSB PDB ID code of the X-ray structure of 7 bound to MMP-13 is 2PJT.
25. Duan J.J.-W., Chen L., Wasserman Z.R., Lu Z., Liu R.-Q., Covington M.B., Qian M., Hardman K.D., Magolda R.L., Newton R.C., Christ D.D., Wexler R.R., and Decicco C.P. J. Med. Chem. 45 (2002) 4954-4957
26. For descriptions of all the in vitro and in vivo assays used herein, see:. Zhang Y., Xu J., Levin J., Hegen M., Li G., Robertshaw H., Brennan F., Cummons T., Clarke D., Vansell N., Nickerson-Nutter C., Barone D., Mohler K., Black R., Skotnicki J., Gibbons J., Feldmann M., Frost P., Larsen G., and Lin L. J. Pharmacol. Exp. Ther. 309 (2004) 348-355
27. Bender, S. L.; Melnick, M. J. U.S. Patent 5,753,653, 1998; Chem. Abstr., 1998, 129, 16140.